最近,两种酪氨酸激酶抑制剂索拉非尼和舒尼替尼被用来治疗肾细胞癌。很多患者由于对第一种药物缺少持续的效果,而连续服用第二种酪氨酸激酶抑制剂。为了解这种序贯疗法的有效性和安全性,作者分析了90例接受序贯治疗的肾细胞患者对索拉非尼和舒尼替尼是否存在交叉耐药,这些患者? Recently, two tyrosine kinase inhibitors, sorafenib and sunitinib, have been used to treat renal cell carcinoma. Many patients continue to take a second tyrosine kinase inhibitor due to the lack of a sustained effect on the first drug. To understand the effectiveness and safety of this sequential therapy, the authors analyzed whether 90 patients with sequentially treated renal cells had a presence of cross-resistance to sorafenib and sunitinib.